Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use in this Registration Statement (No. 333-274230) on Form S-4 of our report dated March 30, 2023, relating to the financial statements of Ambrx Biopharma, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

 

/s/ Deloitte & Touche LLP

San Diego, California

September 12, 2023